IPP Bureau
Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
By IPP Bureau - June 24, 2025
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Biocon Biologics collaborates with National Cancer Society Malaysia
By IPP Bureau - June 24, 2025
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Merck announces Phase 3 hyperion study of Winrevair met primary endpoint in recently diagnosed adults with PAH
By IPP Bureau - June 24, 2025
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
By IPP Bureau - June 23, 2025
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
Sai Life Sciences commences commercial operation of 2nd phase in Bidar
By IPP Bureau - June 23, 2025
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
By IPP Bureau - June 23, 2025
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Emcure to acquire remaining stake in Zuventus Healthcare
By IPP Bureau - June 23, 2025
The transaction is expected to close in Q2 FY 2026
Unichem receives Form 483 from USFDA with 3 observations for Roha API facility
By IPP Bureau - June 23, 2025
The company will provide the necessary response to USFDA within stipulated 15 days
BASF opens new GMP Solution Center in US
By IPP Bureau - June 23, 2025
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Biocon concludes a Rs 4,500 crore equity fundraise through QIP
By IPP Bureau - June 21, 2025
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study
By IPP Bureau - June 21, 2025
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
By IPP Bureau - June 21, 2025
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia
By IPP Bureau - June 21, 2025
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Healthcare Triangle launches Malaysian subsidiary QuantumNexis
By IPP Bureau - June 20, 2025
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
